封面
市場調查報告書
商品編碼
1098530

癌症診斷的全球市場預測(~2028年):各技術,各用途,各地區的分析

Cancer Diagnostics Market Forecasts to 2028 - Global Analysis By Technology (Instrument-Based, Platform-Based Diagnostics), Application (Blood Cancer, Breast Cancer, Cervical Cancer), and By Geography

出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

全球癌症診斷的市場規模在2021年估算為178億2,000萬美金,在預測期間內預計將以13.5%的年複合成長率擴大,2028年之前達到432億4,000萬美元。

這份報告提供全球癌症診斷市場調查,提供市場的推動因素與阻礙因素,市場機會,COVID-19影響,各市場區隔的市場分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 摘要整理

第2章 序文

第3章 市場趨勢分析

  • 促進因素
  • 阻礙因素
  • 市場機會
  • 威脅
  • 技術分析
  • 用途分析
  • 終端用戶分析
  • 新興市場
  • COVID-19影響

第4章 波特的五力分析

第5章 全球癌症診斷市場:各技術

  • 設備為基礎的
    • 切片檢查
    • 液態切片
    • 影像診斷
  • 平台為基礎的
    • 聚合酵素鏈鎖反應(PCR)
    • 次世代定序(NGS)
    • 微陣列
    • 原位雜交(ISH)
    • 免疫組織化學(IHC)
    • 流式細胞技術
  • 腫瘤生物標記檢驗
    • 胎兒球蛋白(AFP)檢驗
    • 鹼性磷酸酶(ALP)檢驗
    • 乳癌(BRCA)遺傳基因檢驗
    • CA-19檢驗
    • 癌胚抗原)檢驗
    • 循環腫瘤細胞(CTC)檢驗
    • EGFR變異實驗
    • 人類表皮生長因子受體2(HER2)
    • 克爾斯滕大鼠肉瘤病毒(KRAS)變異實驗
    • 攝護腺特異性抗原(PSA)檢驗

第6章 全球癌症診斷市場:各用途

  • 血液癌症
  • 乳癌
  • 子宮頸癌症
  • 結腸直腸癌症
  • 腎臟癌症
  • 肝臟癌症
  • 肺癌症
  • 黑色素瘤
  • 卵巢癌症
  • 胰臟癌症

第7章 全球癌症診斷市場:各終端用戶

  • 醫院相關檢驗所
  • 診斷研究所
  • 癌症研究機關

第8章 全球癌症診斷市場:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東·非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東·非洲

第9章 主要發展

  • 契約,夥伴關係,合作,合資企業
  • 收購與合併
  • 新產品的銷售
  • 擴張
  • 其他的重要策略

第10章 企業簡介

  • Abbott Diagnostics
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • bioMerieux
  • C.R. Bard, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare (A Subsidiary of General Electric Company)
  • Hologic,Inc.
  • Illumina, Inc.
  • Koninklijke Philips N.V.
  • Qiagen
  • Roche Diagnostics
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific, Inc.
Product Code: SMRC21562

According to Stratistics MRC, the Global Cancer Diagnostics Market is accounted for $17.82 billion in 2021 and is expected to reach $43.24 billion by 2028 growing at a CAGR of 13.5% during the forecast period. Cancer diagnostics is a method of identifying different biomarkers, proteins, and some signs that lead to the identification of the presence of a cancerous tumor. Efficient diagnostic testing is used to validate or rule out the existence of illness, monitor the progression of the disease, and schedule & review treatment outcomes. Diagnostic procedures for cancer may include imaging, tumor biopsy, laboratory tests (including tests for tumor markers), endoscopic examination, surgery, or genetic testing.

Market Dynamics:

Driver:

Development in the number of private diagnostic centers

The number of private diagnostic centers is rising across the globe as there is a rising demand for diagnostic imaging procedures and an increasing burden on public hospitals owing to the limited number of imaging modalities at their disposal. Favorable healthcare policies, coupled with high per capita healthcare spending, have created a conducive environment for the adoption of advanced cancer diagnostic technologies such as imaging. Strategies undertaken by these companies include product launches and expansion plans, which will drive market growth.

Restraint:

High cost

The rising demand for tests coupled with technological advancements with faster results and accuracy has escalated the price associated with imaging cancer diagnostics. The practice of imaging diagnostics has grown exponentially over the last decade in the industry. Though, in numerous countries, it is observed that some cancer diagnostic services are not fully covered by insurance.

Opportunity:

Recommendations for cancer screening, Introduction of novel diagnostic biomarkers

The identification of prospective cancer biomarkers has been made possible by technological developments in the field of biotechnology, and some of these biomarkers have been marketed. The introduction of novel diagnostic biomarkers is creating lucrative opportunities for the growth of the market. Moreover, to detect cancer in the early stages and bring down the mortality rate, governments in advanced countries and primary care doctors are recommending cancer screening tests for patients. The increased understanding of certain cancer biomarkers is creating a huge commercial opportunity for treating cancer patients through improved detection technology and equipment.

Threat:

Insufficient reimbursement policies

Inadequate reimbursement policies are predictable to threaten the growth of the market. There have been numerous advancements in radiology concerning imaging equipment in the recent past. Moreover, most medical insurance companies do not offer reimbursement for procedures using Computer-aided Detection (CAD). Thus, people tend to choose conventional methods for diagnosis such as biopsy, pathological tests, or conventional imaging methods such as mammography, and MRI procedures.

Breast Cancer segment is expected to be the largest during the forecast period

The breast cancer category is the largest segment in the market, due to upsurge in older women population and increase in breast cancer prevalence between the women. Moreover, the market will gain traction owing to an increase in the number of initiatives conducted by numerous groups are some of the factor foster the segment growth.

The Hospital Associated Labs segment is expected to have the highest CAGR during the forecast period

The hospitals segment accounted for the largest share of the market, owing to the increasing number of in-house diagnostic procedures performed in hospitals, the growing number of patients visiting hospitals, and rising consciousness regarding early diagnosis is the major driving factor for this market.

Region with highest share:

The North America is projected to hold the highest market share, owing to developed healthcare infrastructure, government initiatives toward public health care are expected to drive this dominance. Moreover, the rise in cancer cases, the presence of key manufacturers, well-established healthcare infrastructure, and rising awareness regarding cancer and its proper management. The additionally rising presence of numerous biotechnology as well as medical device companies, rising greater funding available for research and development projects, and high adoption of advanced technologies in this province are some of the factors driving the market growth in the province.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR, The growth is accredited to the rise in the medical tourism market, and the increase in the prevalence of cancer disease in countries of this area is favouring the market growth. The Asia Pacific is also flourishing owing to medical tourism, increasing awareness, and investment in private diagnostic centers. This is owing to the presence of a huge patient population, a well-defined regulatory system that favours fast product approvals, and the accessibility of qualified personnel at a reduced cost.

Key players in the market:

Some of the key players profiled in the Cancer Diagnostics Market include Abbott Diagnostics, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMerieux, C.R. Bard, Inc., F. Hoffmann-La Roche Ltd., GE Healthcare (A Subsidiary of General Electric Company), Hologic,Inc, Illumina, Inc, Koninklijke Philips N.V, Qiagen, Roche Diagnostics, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc.

Key developments:

In July 2020: F. Hoffmann-La Roche Ltd launched the uPath PD-L1 image analysis for non-small cell lung cancer, which is an automated digital pathology algorithm.

In November 2021: Hologic, Inc. commercially launched its new Genius™ Digital Diagnostics System in Europe. The Genius Digital Diagnostics System is the next generation of cervical cancer screening that combines deep learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and Cervical Cancer cells in women.

In March 2021: Agilent Technologies Inc. acquired Resolution Bioscience, to reinforce its headship position in cancer diagnostics and in September 2020, Illumina, Inc. acquired GRAIL to launch a new phase of a cancer diagnosis. This acquisition is aimed to accelerate the adoption and commercialization of transformative multi-cancer diagnosis test with the prospective to detect more cancers earlier and enable better outcomes..

Technology's Covered:

  • Instrument-Based
  • Platform-Based Diagnostics
  • Tumor Biomarkers Tests

Applications Covered:

  • Blood Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Kidney Cancer
  • Liver Cancer
  • Lung Cancer
  • Melanoma
  • Ovarian Cancer
  • Pancreatic Cancer

End Users Covered:

  • Hospital Associated Labs
  • Diagnostic Laboratories
  • Cancer Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025 and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Diagnostics Market, By Technology

  • 5.1 Introduction
  • 5.2 Instrument-Based
    • 5.2.1 Biopsies
      • 5.2.1.1 Bone Marrow Biopsy
      • 5.2.1.2 Endoscopic Biopsy
      • 5.2.1.3 Needle Biopsy
    • 5.2.2 Liquid Biopsy
    • 5.2.3 Diagnostic Imaging
      • 5.2.3.1 Ultrasound
      • 5.2.3.2 Mammography
      • 5.2.3.3 Magnetic Resonance Imaging (MRI)
      • 5.2.3.4 Computed Tomography (CT) `
      • 5.2.3.5 Positron Emission Tomography (PET)
      • 5.2.3.5.1 Standalone Positron Emission Tomography `
      • 5.2.3.5.2 Hybrid Positron Emission Tomography
  • 5.3 Platform-Based Diagnostics
    • 5.3.1 Polymerase Chain Reaction (PCR)
    • 5.3.2 Next-Generation Sequencing (NGS)
    • 5.3.3 Microarrays
    • 5.3.4 In Situ Hybridization (ISH)
    • 5.3.5 Immunohistochemistry (IHC)
    • 5.3.6 Flow Cytometry
  • 5.4 Tumor Biomarkers Tests
    • 5.4.1 Alpha-Fetoprotein (AFP) Tests
    • 5.4.2 Alkaline Phosphatase (ALP) test
    • 5.4.3 Breast Cancer (BRCA) Gene Test
    • 5.4.4 CA-19 Tests
    • 5.4.5 Carcinoembryonic Antigen) Test
    • 5.4.6 Circulating Tumor Cell (CTC) Test
    • 5.4.7 EGFR Mutation Tests
    • 5.4.8 Human Epidermal Growth Factor Rceptor 2 (HER2)
    • 5.4.9 Kirsten Rat Sarcoma Virus (KRAS) Mutation Tests
    • 5.4.10 Prostate-Specific Antigen (PSA) Test

6 Global Cancer Diagnostics Market, By Application

  • 6.1 Introduction
  • 6.2 Blood Cancer
  • 6.3 Breast Cancer
  • 6.4 Cervical Cancer
  • 6.5 Colorectal Cancer
  • 6.6 Kidney Cancer
  • 6.7 Liver Cancer
  • 6.8 Lung Cancer
  • 6.9 Melanoma
  • 6.10 Ovarian Cancer
  • 6.11 Pancreatic Cancer

7 Global Cancer Diagnostics Market, By End User

  • 7.1 Introduction
  • 7.2 Hospital Associated Labs
  • 7.3 Diagnostic Laboratories
  • 7.4 Cancer Research Institutes

8 Global Cancer Diagnostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott Diagnostics
  • 10.2 Agilent Technologies, Inc.
  • 10.3 Becton, Dickinson and Company
  • 10.4 bioMerieux
  • 10.5 C.R. Bard, Inc.
  • 10.6 F. Hoffmann-La Roche Ltd.
  • 10.7 GE Healthcare (A Subsidiary of General Electric Company)
  • 10.8 Hologic,Inc.
  • 10.9 Illumina, Inc.
  • 10.10 Koninklijke Philips N.V.
  • 10.11 Qiagen
  • 10.12 Roche Diagnostics
  • 10.13 Siemens Healthcare GmbH
  • 10.14 Thermo Fisher Scientific, Inc.

List of Tables

  • Table 1 Global Cancer Diagnostics Market Outlook, By Region (2020-2028) (US $MN)
  • Table 2 Global Cancer Diagnostics Market Outlook, By Technology (2020-2028) (US $MN)
  • Table 3 Global Cancer Diagnostics Market Outlook, By Instrument-Based (2020-2028) (US $MN)
  • Table 4 Global Cancer Diagnostics Market Outlook, By Biopsies (2020-2028) (US $MN)
  • Table 5 Global Cancer Diagnostics Market Outlook, By Liquid Biopsy (2020-2028) (US $MN)
  • Table 6 Global Cancer Diagnostics Market Outlook, By Diagnostic Imaging (2020-2028) (US $MN)
  • Table 7 Global Cancer Diagnostics Market Outlook, By Platform-Based Diagnostics (2020-2028) (US $MN)
  • Table 8 Global Cancer Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2020-2028) (US $MN)
  • Table 9 Global Cancer Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2020-2028) (US $MN)
  • Table 10 Global Cancer Diagnostics Market Outlook, By Microarrays (2020-2028) (US $MN)
  • Table 11 Global Cancer Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2020-2028) (US $MN)
  • Table 12 Global Cancer Diagnostics Market Outlook, By Immunohistochemistry (IHC) (2020-2028) (US $MN)
  • Table 13 Global Cancer Diagnostics Market Outlook, By Flow Cytometry (2020-2028) (US $MN)
  • Table 14 Global Cancer Diagnostics Market Outlook, By Tumor Biomarkers Tests (2020-2028) (US $MN)
  • Table 15 Global Cancer Diagnostics Market Outlook, By Alpha-Fetoprotein (AFP) Tests (2020-2028) (US $MN)
  • Table 16 Global Cancer Diagnostics Market Outlook, By Alkaline Phosphatase (ALP) test (2020-2028) (US $MN)

Table17 Global Cancer Diagnostics Market Outlook, By Breast Cancer (BRCA) Gene Test (2020-2028) (US $MN)

  • Table 18 Global Cancer Diagnostics Market Outlook, By CA-19 Tests (2020-2028) (US $MN)
  • Table 19 Global Cancer Diagnostics Market Outlook, By Carcinoembryonic Antigen) Test (2020-2028) (US $MN)
  • Table 20 Global Cancer Diagnostics Market Outlook, By Circulating Tumor Cell (CTC) Test (2020-2028) (US $MN)
  • Table 21 Global Cancer Diagnostics Market Outlook, By Epidermal Growth Factor Receptor Gene (EGFR) Mutation Tests (2020-2028) (US $MN)
  • Table 22 Global Cancer Diagnostics Market Outlook, By Human Epidermal Growth Factor Rceptor 2 (HER2) (2020-2028) (US $MN)
  • Table 23 Global Cancer Diagnostics Market Outlook, By Kirsten Rat Sarcoma Virus (KRAS) Mutation Tests (2020-2028) (US $MN)
  • Table 24 Global Cancer Diagnostics Market Outlook, By Prostate-Specific Antigen (PSA) Test (2020-2028) (US $MN)
  • Table 25 Global Cancer Diagnostics Market Outlook, By Application (2020-2028) (US $MN)
  • Table 26 Global Cancer Diagnostics Market Outlook, By Blood Cancer (2020-2028) (US $MN)
  • Table 27 Global Cancer Diagnostics Market Outlook, By Breast Cancer (2020-2028) (US $MN)
  • Table 28 Global Cancer Diagnostics Market Outlook, By Cervical Cancer (2020-2028) (US $MN)
  • Table 29 Global Cancer Diagnostics Market Outlook, By Colorectal Cancer (2020-2028) (US $MN)
  • Table 30 Global Cancer Diagnostics Market Outlook, By Kidney Cancer (2020-2028) (US $MN)
  • Table 31 Global Cancer Diagnostics Market Outlook, By Liver Cancer (2020-2028) (US $MN)
  • Table 32 Global Cancer Diagnostics Market Outlook, By Lung Cancer (2020-2028) (US $MN)
  • Table 33 Global Cancer Diagnostics Market Outlook, By Melanoma (2020-2028) (US $MN)
  • Table 34 Global Cancer Diagnostics Market Outlook, By Ovarian Cancer (2020-2028) (US $MN)
  • Table 35 Global Cancer Diagnostics Market Outlook, By Pancreatic Cancer (2020-2028) (US $MN)
  • Table 36 Global Cancer Diagnostics Market Outlook, By End User (2020-2028) (US $MN)
  • Table 37 Global Cancer Diagnostics Market Outlook, By Hospital Associated Labs (2020-2028) (US $MN)
  • Table 38 Global Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2020-2028) (US $MN)
  • Table 39 Global Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2020-2028) (US $MN)

Note- Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.